Background
==========

Chronic obstructive pulmonary disease (COPD) constitutes a major and progressive health care problem worldwide and is expected to be the third cause of death globally over the next 20 years.[@b1-copd-5-407] Besides smoking cessation, pulmonary rehabilitation is the recommended treatment and has been proven to be effective across the whole spectrum of COPD patients.[@b2-copd-5-407]--[@b5-copd-5-407] A recent meta-analysis shows that pulmonary rehabilitation relieves dyspnea and fatigue, improves mental status, and enhances patients' control over their disease.[@b6-copd-5-407] However, despite proven efficacy, pulmonary rehabilitation is still only available for a small proportion of the worst patients, due to capacity problems and high costs.[@b7-copd-5-407] It is expected that the rise in prevalence of COPD will progressively cause an even higher burden on rehabilitation programmers in the future.

At present, the majority of COPD patients are treated in primary care, and approximately 80% suffer from mild to moderate disease.[@b8-copd-5-407] As a result, general practitioners often find themselves at a crossroads in the organization of care for COPD patients. Nevertheless, interdisciplinary cooperation between primary health care providers, as well as primary and secondary care, is often needed. In earlier reports[@b9-copd-5-407],[@b10-copd-5-407] we hypothesized that if components of pulmonary rehabilitation were tailored into an integrated disease management (IDM) program available for primary care and carried out by a multidisciplinary, integrated care team, the benefits of pulmonary rehabilitation could be extended to a larger population of COPD patients in need. This would explicitly include those with milder stages of disease, given that they have sufficient symptom burden to justify an integrated intervention. Elements that can often be integrated include smoking cessation, exacerbation management, optimal medication, self-management, patient education, dietary intervention, and an exercise program.

In an earlier paper, we demonstrated that our IDM program in primary care improved health status in a clinically relevant way in patients with mild to moderate COPD at 12 months' follow-up. The greatest room for improvement was shown in COPD patients with a Medical Research Council (MRC) dyspnea score \>2.[@b9-copd-5-407] After we had demonstrated 12 months' efficacy of the IDM program in a controlled setting, a real-life implementation cohort was set up in the city of Rotterdam. In this pragmatic IDM program, we focused on improving exercise capacity because we believed this would be an important driver to sustain effectiveness. Currently, long-term results of pulmonary rehabilitation programs are mixed, and some authors report that most benefits of pulmonary rehabilitation dissipate over time.[@b11-copd-5-407]--[@b13-copd-5-407] Similarly, the longer-term effect of IDM in primary care is still unclear. The aim of the present study was to determine the long-term effects of IDM on health status and exercise capacity in primary care COPD patients.

Methods
=======

We analyzed 24 months of follow-up data for primary care IDM programs in the Bocholtz controlled clinical trial and the Kroonluchter implementation cohort. Both study populations consisted of primary care patients with chronic respiratory symptoms and a postbronchodilator forced expiratory volume in one second/forced vital capacity (FEV~1~/FVC) \< 0.7, in accordance with national and international guidelines.[@b3-copd-5-407],[@b8-copd-5-407] Exclusion criteria were terminal illness, immobility, substance abuse, and inability to fill in questionnaires. In the Bocholtz clinical trial, the regional Medical Ethics Committee of the Atrium Medical Centre, Heerlen, approved the study protocol. All participating patients gave their written informed consent. In the Kroonluchter cohort, all patients gave their written informed consent for participation in the implementation program.

In the following section we provide a brief description of both study settings and designs. We refer to our previous publications for an extensive description of the clinical one-year results and methods for the Bocholtz study,[@b9-copd-5-407] as well as the background and design of the Kroonluchter IDM program.[@b10-copd-5-407]

Picasso Bocholtz study
----------------------

The Picasso Bocholtz study was a controlled clinical trial assessing the effects of IDM on health status in COPD patients from two comparable primary health care centers in the south of The Netherlands. Patients were followed up for two years, during which time the intervention group received an IDM program and the control group received usual care. Patients were included based on chronic respiratory complaints, postbronchodilator lung function testing, and adequate workup in case of more complex disease by a local pulmonologist, on indication by the patients' primary care physician. In the intervention setting, an integrated COPD management team was formed, including two physiotherapists, a respiratory nurse, a physician assistant, a dietician, a pharmacist, a supervising primary care physician, and a logistics manager. All team members contributed in their area of expertise to a standardized written treatment protocol, which included different elements of IDM, based on the joint American Thoracic Society/European Respiratory Society COPD standards.[@b14-copd-5-407] Examples included personalized physical activity training programmers, optimal medication prescribing and adherence monitoring, rapid action plans for exacerbations, and continuous self-management education.[@b9-copd-5-407]

Kroonluchter cohort
-------------------

Based on the encouraging results of the Bocholtz study, the Kroonluchter integrated disease management program was implemented in a low socioeconomic status borough in Rotterdam. Since 2006, a total of 216 primary care patients with chronic respiratory complaints have been included after clinical assessment, including postbronchodilator lung function testing, confirmed eligibility according to GOLD (Global Initiative for Chronic Obstructive Lung Disease) criteria. A multidisciplinary dedicated team of primary care physicians, nurse specialists, and physiotherapists was formed and trained to establish a locally agreed collaborative protocol. Diagnostic workup in case of complex disease was provided by collaborating pulmonologists, after referral by the primary care physician. In cooperation with the patient, an individualized plan of action was designed, based on an explicitly formulated personal target, varying from "quitting smoking with guidance within six months" to "climbing a short flight of stairs without hindrance by feelings of dyspnea within six months". Based on disease burden and patient needs, an individual program was assembled, which could include self-management training and exacerbation management, an exercise training program, smoking cessation strategies, better medication use, and personalized disease education.

In case of obesity or muscular depletion, referral to a dietician for dietary intervention was possible. Because of good local collaboration and arrangements for additional workup, patients could be referred to pulmonary physicians at short notice. In addition, extra attention was given to follow-up of patients after an exacerbation. Patients with an MRC dyspnea score \>2 or patients known by their primary care physician to be inactive were assigned to a six-month COPD-specific training program run by specialized physiotherapists. Physical exercise training consisted of one month of individual training, followed by five months of group training. Training was focused on strength as well as endurance exercises, and was tailored to the individual abilities and limitations of the patient. Patients trained for one hour twice per week under supervision and were instructed to train one hour per week at home. After six months, there was a follow-up of one hour per week in order to sustain any effects over time.[@b10-copd-5-407]

Outcomes and measurements
-------------------------

Baseline measurements in both studies included age, gender, smoking habits, body mass index, lung function, and score on the MRC dyspnea scale (a short and valid questionnaire to quantify dyspnea).[@b15-copd-5-407]

In the Bocholtz study, the Clinical COPD Questionnaire (CCQ) was used to assess health status, because it is well validated and easy to administer in primary care.[@b15-copd-5-407] Primary outcome at 24 months in the Bocholtz study was the difference in CCQ at 24 months compared with baseline CCQ score in both the intervention and control groups.

In the Kroonluchter cohort, the six-minute walking distance (6MWD), a measure of functional capacity, was conducted according to international recommendations.[@b16-copd-5-407] The 6MWD is a practical, self-paced test, measuring the maximum distance subjects can walk in six minutes. The primary outcome of this program was the difference in 6MWD at 24 months compared with baseline 6MWD score.

Power calculations
------------------

In the Bocholtz study, we calculated that a sample size of 2 × 45 patients was needed (with a power of 80% and α = 0.05) to detect a minimum clinically important difference of −0.4 unit change in quality of life on the CCQ.[@b15-copd-5-407]

Because the Kroonluchter project was designed as an ongoing implementation program, no formal group comparison or power calculation was conducted. On the basis of earlier studies and a minimum clinically important difference of 54 m, which represents the threshold value for a clinically significant change on the 6MWD,[@b16-copd-5-407] a minimum group size of 50 patients was deemed necessary to analyze 24-month results. In this study, the first batch of consecutive COPD patients completing 6MWD measurements at baseline and months 3, 6, 12, and 24 were analyzed.

Statistical analysis
--------------------

Data were analyzed using SPSS version 13, using independent *t*-tests and Chi-square tests for comparison of baseline characteristics. Baseline and annual differences in CCQ (Bocholtz) and 6MWD (Kroonluchter) were compared using paired-sample *t*-tests. In prespecified subgroup analyses, the differential effects of baseline CCQ score, MRC score, and 6MWD were investigated.

Results
=======

Patients
--------

In the Bocholtz study, 106 COPD patients diagnosed according to GOLD classification were analyzed for baseline measurements, comprising 59 patients in the intervention group and 47 patients in the control group. This initial COPD population is described in [Table 1](#t1-copd-5-407){ref-type="table"}. Subjects were of mean age 64 years, with an average postbronchodilator FEV~1~ of 63% predicted (standard deviation 19) and an FEV~1~/FVC ratio of 0.56. There were no significant differences in demographic variables, smoking habits, or lung function between the intervention and control groups at baseline. Of the initial population of 106 patients, 86 patients (81%) completed a follow-up of two years (44 in the intervention group and 42 in the control group) and could be further analyzed.

Of the original group of 216 patients in the Kroonluchter cohort, 39 (18%) dropped out due to relocation, severe comorbidity, or unwillingness to fill out repeated questionnaires. Of the initial 216 patients, 104 (48%) were referred to a physiotherapy training program, based on MRC dyspnea score \>2 or inactivity that necessitated an integrated approach. So far, 56 patients (54%) have completed the 24-month 6MWD test, and their data could be used for analysis. [Table 2](#t2-copd-5-407){ref-type="table"} shows the baseline characteristics of the initial cohort and the group that finished 24 months of follow-up. The mean age of the latter group was 69 years, with an FEV~1~/FVC ratio of 0.59, while their postbronchodilator FEV~1~ of 65% was somewhat lower than in the total group (71%).

Primary outcome in Bocholtz study
---------------------------------

[Table 3](#t3-copd-5-407){ref-type="table"} shows the long-term changes in CCQ scores in COPD patients in the intervention and control groups of the Bocholtz study. Compared with baseline, a statistically significant change of −0.4 is sustained in the intervention group during 24 months, while the control group shows nonsignificant changes during 24 months. The prespecified subgroup analysis of patients with baseline CCQ \> 1 shows a statistically significant and clinically relevant difference of −0.9, while the control group shows no significant improvement. In patients with MRC scores \>2, the effect on CCQ score is tripled and shows a statistically significant and clinically relevant difference of −1.2, compared with a nonsignificant change of −0.02 in the control group.

Primary outcome in Kroonluchter cohort
--------------------------------------

[Table 4](#t4-copd-5-407){ref-type="table"} shows the long-term changes in 6MWD in the Kroonluchter cohort at months 3, 6, 12, and 24. The 6MWD improves significantly and in a clinically relevant manner up to 93 m at 12 months, and remains at 83 m over 24 months. In patients with MRC scores \>2, 6MWD differences are comparable in significance and clinical relevance, but seem to occur somewhat earlier, ie, at three months. In patients with baseline 6MWD \< 400 m, the 6MWD difference is 112 m at 12 months and remains statistically significant and clinically relevant at 24 months, with effect sizes over 100 m.

Discussion
==========

Our studies demonstrate that IDM programs can be successfully implemented in real-life primary care populations. Even after two years, considerable proportions of the patients involved in the programs still show significant and clinically relevant improvements in health status and exercise tolerance. In patients with a baseline CCQ \> 1 and in those with MRC dyspnea score \>2, the long-term effect on CCQ score seems to be doubled and even tripled, respectively. In patients with baseline 6MWD \< 400 m, the 6MWD difference remains substantially large over two years, with effect sizes exceeding 100 m.

A typical structured program of pulmonary rehabilitation in the secondary and tertiary care setting is usually of relatively short duration, ranging from 6 to 12 weeks.[@b17-copd-5-407] Positive results up to three months have been widely published,[@b6-copd-5-407],[@b17-copd-5-407]--[@b19-copd-5-407] but several clinical trials have reported that initial benefits of the intervention tend to recede over time, and that effects above clinical relevance thresholds are lost again at six to 18 months' follow-up.[@b11-copd-5-407]--[@b13-copd-5-407],[@b20-copd-5-407],[@b21-copd-5-407]

As a result, recommendations regarding prolonged duration of pulmonary rehabilitation have been issued, and several studies have evaluated longer-term programs in more severe patients, with inconclusive results. Guell randomized 60 GOLD Stage III COPD patients to 12 months of intervention or standard care and followed them up for two years. Benefits on exercise tolerance, dyspnea, and quality of life were accrued, but diminished in the second year of follow-up.[@b22-copd-5-407] In a randomized controlled study in moderate to very severe COPD patients, Berry et al concluded that an 18-month exercise program resulted in greater improvements in self-reported disability and physical functioning when compared with a three-month exercise program.[@b4-copd-5-407] Wijkstra et al reported improvements in quality of life over 18 months in GOLD Stage III patients following rehabilitation at home for three months, followed by physiotherapy sessions once a month. However, the authors concluded that change in quality of life was not associated with a change in exercise tolerance.[@b23-copd-5-407] Positive findings in selected patient groups in secondary and tertiary care, following a prolonged pulmonary rehabilitation program, were further confirmed by Troosters et al, Engstrom et al, and Bendstrup et al, suggesting that structured, supervised exercise participation should be continued for extended periods in patients undergoing pulmonary rehabilitation.[@b24-copd-5-407]--[@b26-copd-5-407]

To the best of our knowledge, this is the first study describing long-term follow-up results of IDM in primary care. Our positive results can be explained by two important differences, as compared with the mixed results summarized earlier. First, we studied the effect of IDM programs developed especially for primary care, which consist of an interdisciplinary approach involving different primary health care team members, aided by secondary care where needed. Furthermore, other pulmonary rehabilitation studies usually included more severe COPD patients, while our programs were directed at the whole range of COPD patients, including those with milder stages of disease, but with sufficient symptom burden to justify intervention.

Our results are probably more in line with the recent INTERCOM (Interdisciplinary Community-Based COPD Management Program) study that included secondary care COPD patients with less advanced airflow obstruction, but impaired exercise capacity. In this randomized controlled trial, the intervention group received exercise training, education, nutritional therapy, and smoking cessation counseling in a community-based, multidisciplinary setting. Quality of life, functional exercise capacity, and breathlessness remained significantly favorable in the intervention group versus usual care over the entire two-year intervention.[@b27-copd-5-407]

It is well known that COPD patients have a less active lifestyle compared with healthy elderly persons.[@b28-copd-5-407] One study by Pitta et al showed that significant improvements in time spent walking in daily life were only obtained after six months of rehabilitation, but were not present at three months.[@b29-copd-5-407] These findings are mirrored in our Kroonluchter cohort results for the 6MWD, stressing the importance of implementing programs for at least six months to optimize the potential for improvement. It is likely that benefits achieved after following an exercise program tend to dissipate after the initial intervention and when the accompanying supervision terminates. Therefore, we successfully developed a training program which included extra follow-up training of one hour per week after the initial six months, intended to enhance social support in the training groups and sustain results in the long term. It is likely that our clinically relevant and statistically significant results on the 6MWD at 24 months of follow-up are the result of more prolonged supervision by physiotherapists and the peer support offered in the training groups.

Our studies had several methodologic limitations. The Bocholtz program was designed as a clinical controlled trial, but was not randomized, because it was primarily developed to measure a maximally achievable effect of an IDM program at a primary care practice level. Indeed, the study setting was chosen to include demographically comparable villages but with limited interaction in daily life, resulting in near absence of contamination between groups.[@b12-copd-5-407] The Kroonluchter cohort was based on lessons learned from the Bocholtz study, and was primarily developed as an implementation program in a real-life setting. As a result, a power calculation was not done beforehand. Nevertheless, our significant 6MWD results at 24 months reached far beyond the minimum clinically important difference of 54 m, demonstrating an adequate sample size. The first adequate batch of consecutive COPD patients completing 6MWD measurements at 24 months analyzed in this study may represent selection of more motivated patients, although their baseline characteristics differed little from the total group (see [Table 2](#t2-copd-5-407){ref-type="table"}). Indeed, we have observed that higher levels of intrinsic motivation usually come with a higher burden of symptoms at baseline. This may be part of the reason that indicators of disease burden (CCQ \> 1, MRC dyspnea score \>2, 6MWD \< 400 m) do seem to increase the chances of achieving clinically relevant effects on health status in patients with mild to moderate COPD. These results suggest a potential usefulness of phenotypic profiling in a primary care COPD population, which we intend to study further, and we recommend that other research groups do so as well.

Regaining control over one's own disease state is probably a crucial factor in the success of both of our programs. During the IDM program, improved feelings of self-efficacy and independence became notable in participating patients. Overall, the greatest improvements were found in patients with a baseline MRC dyspnea score \>2, and to a lesser extent in patients with CCQ \> 1. At this stage, lung function is still relatively well maintained and thus patients perceive a tangible change in symptom burden. When asked, they felt more capable of actually breaking through the vicious circle of inactivity, anxiety, and increasing dyspnea. This was prominently reflected in the patient group with a baseline 6MWD below 400 m, who have achieved the most dramatic improvements in exercise capacity. This cutoff was in fact more sensitive than the 350 m cutoff point used in the BODE (body mass index, obstruction, dyspnea, exercise) index, probably reflecting more room for improvement in primary care COPD patients.[@b30-copd-5-407]

When COPD patients are treated with IDM at an earlier stage, it is likely that costs per patient will be lower, and that larger groups of eligible patients can benefit. Further disease progression in terms of health status and exercise capacity will be positively influenced and, if sustained, even long-term deterioration of lung function may be reduced. We have demonstrated that teams of general practitioners, physiotherapists, and nurse practitioners, supported by pulmonary physicians, can provide adequate IDM designed for primary care, because patients' health status and exercise capacity improved substantially, even after two years of follow-up. In the future, we therefore recommend pragmatic randomized controlled trials addressing the costs and long-term effectiveness of large-scale IDM programs in primary care.

Conclusion
==========

In this study, IDM improved and sustained health status and exercise capacity in primary care COPD patients during two years of follow-up. Improvements in health status were consistently higher in patients with CCQ \> 1 at baseline, being strongest in patients with MRC dyspnea score \>2. Improvements in exercise capacity remain highest in patients with 6MWD \< 400 m at baseline and seem to occur earlier in patients with MRC dyspnea score \>2.
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###### 

Baseline characteristics of intervention versus control group in primary care COPD patients of the Bocholtz study[\*](#tfn1-copd-5-407){ref-type="table-fn"}

                        **Intervention (n = 59)**   **Control (n = 47)**   ***P*value[\#](#tfn2-copd-5-407){ref-type="table-fn"}**
  --------------------- --------------------------- ---------------------- ---------------------------------------------------------
  Age (years)           64.7 (10)                   62.3 (9)               0.99
  Gender (% male)       66.4                        64.3                   0.12
  Current smoking (%)   33.9                        46.8                   0.08
  Body mass index       25.8 (5)                    26.0 (5)               0.75
  FEV~1~ post-BD (%)    63.9 (21)                   61.7 (17)              0.06
  FEV~1~/FVC post-BD    0.55 (.10)                  0.57 (.10)             0.72
  MRC \> 2 (%)          38.6                        33.3                   0.32
  CCQ                   1.4 (1)                     1.6 (1)                0.75

**Notes:**

All values are means (SD) except when stated otherwise;

no significant difference between groups at baseline.

**Abbreviations:** MRC, Medical Research Council dyspnea score; CCQ, Clinical COPD Questionnaire; SD, standard deviation; FEV~1~, forced expiratory volume in one second; FVC, forced vital capacity; BD, bronchodilator.

###### 

Baseline characteristics of total versus 6MWD group in primary care COPD patients of the Kroonluchter cohort[\*](#tfn4-copd-5-407){ref-type="table-fn"}

                        **Total (n = 216)**   **6MWD (n = 56)**   ***P*value**
  --------------------- --------------------- ------------------- --------------------------------------------------
  Age (years)           67.1 (14)             69.2 (10)           0.11
  Gender (% male)       42.1                  37.3                0.38
  Current smoking (%)   41.2                  33.3                0.78
  Body mass index       27.3 (6)              27.8 (5)            0.45
  FEV~1~ post-BD (%)    70.5 (18)             64.5 (17)           0.002[\#](#tfn5-copd-5-407){ref-type="table-fn"}
  FEV~1~/FVC post-BD    0.61 (.12)            0.59 (.14)          0.098
  MRC \> 2 (%)          45.8                  51.9                0.24
  6MWD (m)              364.0 (128)           354.6 (126)         0.44

**Notes:**

All values are means (SD) except when stated otherwise;

significant difference between groups at baseline.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; MRC, Medical Research Council dyspnea score; 6MWD, six-minute walking distance; SD, standard deviation; FEV~1~, forced expiratory volume in one second; FVC, forced vital capacity; BD, bronchodilator.

###### 

Long-term effects of integrated disease management on health status in primary care COPD patients of the Bocholtz study[\*](#tfn7-copd-5-407){ref-type="table-fn"}

                                       **Intervention group**   ***P*value**   **Control group**   ***P*value**                  
  ---------------------------- ------- ------------------------ -------------- ------------------- -------------- -------------- -----
  All patients                                                                                                                   
                               12 mo   −0.4                     (−0.6, −0.2)   0.001               +0.01          (−0.2, 0.2)    0.9
                               24 mo   −0.4                     (−0.7, −0.1)   0.004               +0.02          (−0.4, 0.5)    0.9
  Subgroup baseline CCQ \> 1                                                                                                     
                               12 mo   −0.8                     (−1.1, −0.4)   0.001               −0.1           (−0.3, 0.08)   0.2
                               24 mo   −0.9                     (−1.2, −0.5)   0.001               −0.03          (−0.5, 0.5)    0.9
  Subgroup baseline MRC \> 2                                                                                                     
                               12 mo   −0.9                     (−1.4, −0.4)   0.002               +0.01          (−0.3, 0.3)    1.0
                               24 mo   −1.2                     (−1.8, −0.5)   0.004               −0.02          (−0.8, 0.8)    1.0

**Notes:**

Paired samples *t*-test; *P* is considered significant at values \< 0.05;

minimum clinically important difference CCQ = −0.4.[@b15-copd-5-407]

**Abbreviations:** CCQ, Clinical COPD Questionnaire; CI, confidence interval; MRC, Medical Research Council dyspnea score.

###### 

Long-term effects of integrated disease management on exercise tolerance in primary care chronic obstructive pulmonary disease patients of the Kroonluchter cohort[\*](#tfn10-copd-5-407){ref-type="table-fn"}

                                            **6MWD difference[\*\*](#tfn11-copd-5-407){ref-type="table-fn"} compared with baseline (95% CI)**   ***P*value**    
  --------------------------------- ------- --------------------------------------------------------------------------------------------------- --------------- ----------
  All patients                                                                                                                                                  
                                    3 mo    38.3                                                                                                (27.2, 49.4)    \<0.0001
                                    6 mo    62.5                                                                                                (47.4, 77.7)    \<0.0001
                                    12 mo   93.5                                                                                                (71.4, 115.6)   \<0.0001
                                    24 mo   83.3                                                                                                (60.0, 106.6)   \<0.0001
  Subgroup baseline MRC \> 2                                                                                                                                    
                                    3 mo    52.1                                                                                                (37.1, 67.2)    \<0.0001
                                    6 mo    59.2                                                                                                (40.8, 77.7)    \<0.0001
                                    9 mo    93.0                                                                                                (62.9, 123.1)   \<0.0001
                                    12 mo   80.0                                                                                                (44.7, 115.3)   \<0.0001
  Subgroup baseline 6MWD \< 400 m                                                                                                                               
                                    3 mo    52.7                                                                                                (38.9, 66.5)    \<0.0001
                                    6 mo    78.2                                                                                                (52.5, 103.9)   \<0.0001
                                    9 mo    112.3                                                                                               (77.9, 146.7)   \<0.0001
                                    12 mo   101.4                                                                                               (64.3, 138.6)   \<0.0001

**Notes:**

Paired-samples t-test; *P* is considered significant at values \<0.05;

6MWD = 54 m.[@b17-copd-5-407]

**Abbreviations:** 6MWD, six-minute walking distance; CI, confidence interval; MRC, Medical Research Council dyspnea score.
